drugset
drugset / Trial / NCT04994704

Comparison of Postoperative QoR-15 Scores Between Propofol and Remimazolam

NCT04994704 ↗

Completed 73 enrolled Gangnam Severance Hospital
RandomizedParallel-groupTriple-blindOther

Summary

Remimazolam is a ultra-short-acting benzodiazepine, and unlike conventional benzodiazepine drugs, it is rapidly metabolized in plasma and not accumulates in the body for long periods of infusion or even with high dose administration. In addition, it has no injection pain and infusion syndrome compared with propofol. In particular, there is no study to investigate overall postoperative functional recovery via QoR-15 in patients receiving TIVA using remimazolam. Therefore, rhe purpose of the study is to compare poetoperative quality of recovery (QoR)-15 scores according to the use of anesthetics for total intravenous anesthesia in the cervical spine surgery with intraoperative neurophysiological monitoring.

Timeline

Start
2021-12-01
Primary completion
2023-07-12
Completion
2023-07-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Propofol Small molecule — Intravenous
Comparator Remimazolam Small molecule 0.5 mg/kg Intravenous
Comparator Remimazolam Small molecule 1.5 mg/kg Intravenous
Comparator Remifentanil Small molecule — Intravenous

Indications

No indication recorded.